They're known as the #Werkself , or Factory Eleven. We call them our colleagues. Congrats to Bayer 04 Leverkusen on their first-ever German championship! And the season is not over yet.
Fingers crossed and best wishes from #TeamBayer ⚽ ❤️ #ForOurDream

We’re working with Bayer AG to accelerate the development of AI-powered healthcare applications, saving radiologists time and helping them optimize their work for the benefit of patients. goo.gle/3JdUpSN

#TeamBayer is dedicated to providing impactful #AI solutions to help radiologists reduce workload and provide accurate diagnoses. We’re excited to announce our partnership with Google Cloud to accelerate the power of AI and better serve patient diagnoses. spr.ly/6018wdUQ2

Faster innovation at less cost? Our CEO Bill Anderson shares how we’re aiming to speed up new product launches across #TeamBayer . spr.ly/6014khvRI

+++ Advancing the next generation of blockbuster products +++
Today at our annual Pharma Media Day, we showcased the latest advancements in the transformation of our Bayer Pharmaceuticals business to fuel long-term, sustainable growth.
Learn more here: spr.ly/6013k2M3D

+++ Pipeline #news +++
Bayer announces positive topline data from PIII long-term study confirming path forward for non-hormonal investigational compound for vasomotor symptoms associated w/ menopause.
Learn more: spr.ly/6015kobIS
#WomensHealth #HealthForAll #HungerForNone

Our CEO Bill Anderson shares our strategy with David Faber. Check out more of the interview here:
youtube.com/watch?v=QeQ9-C…

+++ #NEWS +++
Bayer and AIGNOSTICS partner on next generation precision oncology.
Learn more: bayer.com/media/
#teambayer

WE ARE LIVE NOW: Join us in our LinkedIn live discussion with Prof. Dr. Ottmar Edenhofer from @PIK and Matthias Berninger on Industry’s Role following the COP28 resolutions. We appreciate your questions as comments! spr.ly/6016kBmAu

A reminder to join us Monday for our Linkedin live discussion on how businesses can foster a more resilient future. Bayer's Matthias Berninger will be joined by Prof. Dr. Ottmar Edenhofer Potsdam Institute for Climate Impact Research PIK. We welcome and look forward to your questions!
spr.ly/6012Xqx3Y

At the Capital Markets Day in London, our CEO Bill Anderson emphasizes the importance of Bayer's new operating model: „'Dynamic Shared Ownership' will fuel growth through customer proximity and innovation – and focus the entire organization on our customers and products.”

„In 2026, I see a Bayer that has tackled bureaucracy, fully centered on customers and products, with each one of our businesses leaner and more effective than their competitors.' - Bayer CEO Bill Anderson.

Register here to attend our Capital Markets Day: spr.ly/6011X9nyN

The Bayer Group achieved its adjusted guidance for 2023. By 2026, the company aims to enhance performance and regain strategic flexibility. News release: spr.ly/6012Xefda

+++ #NEWS : Update on our Cardiology Portfolio! +++

We are thrilled to share that we are partnering with BridgeBio Pharma with the aim to bring new #cardiology treatment options to patients in need.

Learn more: spr.ly/6010Xk2ci

#TeamBayer #HeartHealth #PatientCare

Today, the Supervisory Board named Julio Triana to the Board of Management of Bayer AG and the President of Bayer Consumer Health. Julio will succeed Heiko Schipper as of May 1st. Read more here: spr.ly/6015XMGDB

Our Supervisory Board is proposing Dr. Nancy Simonian, Lori Schechter, and Jeff Ubben as new members, strengthening the body’s expertise in scientific research, litigation, and capital markets. Read more here: spr.ly/6011XzNSJ

Join us live on Linkedin at 5p.m. CET March 11: Prof. Dr. Ottmar Edenhofer, Director of Potsdam Institute for Climate Impact Research PIK will discuss with Matthias Berninger, Bayer, how businesses can foster a more resilient future in the aftermath of the 28th Conference of the Parties. RSVP here: spr.ly/6015X1KL1

+++ Pipeline #news +++
FDA grants #BreakthroughTherapy designation to Bayer's oral, reversible tyrosine kinase inhibitor being developed for non-small cell lung cancer ( #NSCLC ) harboring HER2 mutations.

Learn more: spr.ly/6016nI0Se
#TeamBayer

+++ Pipeline #news +++
Bayer announced today the start of a Phase II trial with
an investigational first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis. Learn more: spr.ly/6018nuTd2
#TeamBayer

“One of our top priorities is reducing debt and increasing flexibility. Our amended dividend policy, which considered investor input and was not taken lightly, will help us do so.” – Bill Anderson, Bayer CEO
spr.ly/6014nuaXQ